Want to see IN:CIPLA full AI Analyst Report?
Top Page
Cipla Ltd
(CIPLA)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹1,575.00
â–²(11.63% Upside)
Action:Downgraded
Date:05/15/26
The score is primarily supported by strong financial resilience driven by a very conservative balance sheet and solid cash generation, offset by the most recent year’s revenue/margin reset and only moderate technical strength. Valuation is a secondary headwind given the ~25.5 P/E and ~1.0% dividend yield.
Positive Factors
Very strong, low‑debt balance sheet
A very low and declining debt load gives Cipla durable financial flexibility to fund R&D, regulatory compliance, manufacturing investment or opportunistic M&A without stressing liquidity. This conservatism reduces default risk and supports long-term strategic options.
Negative Factors
Sharp revenue decline and margin compression (FY2026)
A large, recent drop in revenue and margins signals structural pressures — lost volume, pricing erosion or product mix shifts — that can erode long-term earnings power. Recovery could require sustained volume gains, pricing improvement, or costly restructuring to restore margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Very strong, low‑debt balance sheet
A very low and declining debt load gives Cipla durable financial flexibility to fund R&D, regulatory compliance, manufacturing investment or opportunistic M&A without stressing liquidity. This conservatism reduces default risk and supports long-term strategic options.
Read all positive factors
Cipla Ltd (CIPLA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.18T
Dividend Yield1.97%
Average Volume (3M)41.77K
Price to Earnings (P/E)35.3
Beta (1Y)0.55
Revenue Growth1.85%
EPS Growth-37.51%
CountryIN
Employees27,764
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)41.74
Shares Outstanding807,845,340
10 Day Avg. Volume63,362
30 Day Avg. Volume41,773
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.87
Price to Sales (P/S)3.51
P/FCF Ratio39.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,474.75Price Target Upside4.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)51.44
Revenue Forecast (FY)₹309.61B
Cipla Ltd Business Overview & Revenue Model
Company Description
Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ing...
How the Company Makes Money
Cipla primarily makes money by selling pharmaceutical products to healthcare channels (including distributors/wholesalers, pharmacies, hospitals, and institutional/government buyers) in India and in international markets. Its core revenue stream i...
Cipla Ltd Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
90
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 281.71B | 281.63B | 272.67B | 255.37B | 225.59B | 217.08B |
| Gross Profit | 147.16B | 120.36B | 180.92B | 164.93B | 141.04B | 130.18B |
| EBITDA | 58.48B | 64.81B | 70.22B | 61.91B | 49.19B | 44.39B |
| Net Income | 33.71B | 38.79B | 52.73B | 41.22B | 28.02B | 25.17B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 424.96B | 373.87B | 327.18B | 294.63B | 271.01B |
| Cash, Cash Equivalents and Short-Term Investments | 100.28B | 100.28B | 106.17B | 77.96B | 62.77B | 46.32B |
| Total Debt | 0.00 | 6.14B | 4.39B | 5.60B | 8.03B | 10.56B |
| Total Liabilities | -345.20B | 79.76B | 60.98B | 59.15B | 57.50B | 59.84B |
| Stockholders Equity | 345.20B | 344.32B | 311.93B | 267.07B | 234.08B | 208.42B |
Cash Flow | ||||||
| Free Cash Flow | 6.80B | 25.27B | 38.43B | 27.85B | 20.55B | 26.25B |
| Operating Cash Flow | 13.45B | 41.26B | 50.05B | 41.34B | 32.38B | 33.26B |
| Investing Cash Flow | 1.59B | -25.33B | -36.91B | -29.88B | -23.89B | -18.72B |
| Financing Cash Flow | -13.18B | -12.12B | -12.93B | -12.00B | -9.58B | -16.00B |
Cipla Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹585.76B | 38.06 | ― | 1.70% | 8.11% | 9.73% | |
71 Outperform | ₹414.85B | 40.14 | ― | 1.60% | 14.50% | 47.08% | |
69 Neutral | ₹1.18T | 35.29 | ― | 2.05% | 1.85% | -37.51% | |
69 Neutral | ₹442.09B | 43.42 | ― | 2.27% | 1.93% | 11.69% | |
68 Neutral | ₹117.19B | 27.99 | ― | 0.44% | 12.51% | 9.82% | |
64 Neutral | ₹219.55B | 30.02 | ― | 1.60% | 10.69% | -9.09% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:CIPLA
Cipla Ltd
1,472.95
-14.29
-0.96%
IN:ABBOTINDIA
Abbott India Limited
27,784.15
-5,123.06
-15.57%
IN:GLAND
Gland Pharma Ltd.
2,504.40
543.47
27.71%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,653.45
-207.77
-7.26%
IN:MARKSANS
Marksans Pharma Limited
258.25
33.65
14.98%
IN:PFIZER
PFIZER LIMITED
4,822.80
-147.17
-2.96%
Cipla Ltd Corporate Events
Cipla Wins U.S. FDA Nod for Generic Advair Diskus, Boosting Respiratory Portfolio
Jul 27, 2026
Cipla has secured U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for a generic version of Advair Diskus, a fluticasone propionate and salmeterol inhalation powder indicated for asthma and COPD. The approval cov...
Cipla posts higher revenue and strong profit in Q1 FY27 unaudited results
Jul 23, 2026
Cipla reported unaudited consolidated revenue from operations of ₹7,119.28 crore for the quarter ended June 30, 2026, up from ₹6,541.20 crore in the preceding quarter, with total income reaching ₹7,330.18 crore. Net profit attrib...
Cipla Discloses Crisil ESG Scores Under SEBI Rules
Jul 12, 2026
Cipla Ltd has received ESG ratings from Crisil ESG Ratings Analytics Limited, a SEBI-registered ESG rating provider, which independently assigned the company a ‘Crisil ESG 69’ and a ‘Crisil Core ESG 66’ score. The disclosu...
Cipla Corrects Typographical Errors in 90th AGM Transcript Filed with Exchanges
Jul 4, 2026
Cipla Limited has issued a corrigendum to its earlier intimation regarding the transcript of its 90th Annual General Meeting, noting that inadvertent typographical errors were identified in the version filed on 3 July 2026. The company has submitt...
Cipla Marks 90 Years at AGM, Reaffirming Focus on Affordable, Responsible Healthcare
Jun 25, 2026
Cipla Ltd marked its 90th Annual General Meeting, held via video conference on 25 June 2026, coinciding with the company’s 90th year since its founding. Chairman Dr Y K Hamied highlighted Cipla’s evolution from limited indigenous opera...
Cipla Appoints B S R & Co. LLP as New Statutory Auditor After AGM Vote
Jun 25, 2026
Cipla Ltd has announced a change in its statutory auditors following shareholder approval at its 90th Annual General Meeting, in line with regulatory requirements. M/s Walker Chandiok Co. LLP has completed its second term, and Cipla has formally ...
Cipla Elevates Shivam Puri to Lead One India Business, Expands Equity Incentives
Jun 16, 2026
Cipla has elevated Shivam Puri, currently managing director and CEO of its consumer arm Cipla Health, to Chief Executive Officer of the One India Business and member of the Management Council, effective 1 July 2026. His appointment signals a push ...
Cipla Elevates Shivam Puri to Lead One India Business, Approves Fresh ESOP Grants
Jun 16, 2026
Cipla has elevated Shivam Puri, currently managing director and CEO of its consumer-focused subsidiary Cipla Health, to the role of chief executive officer for its One India Business and member of the group’s Management Council, effective 1 ...
Cipla Corrects Remote E-Voting Dates for 90th AGM
Jun 9, 2026
Cipla Ltd has issued a correction to its earlier stock exchange filing regarding the schedule for remote e-voting related to its 90th Annual General Meeting for the financial year 2025-26. The company clarified that remote e-voting will run from t...
Cipla outlines TDS rules for proposed FY 2025-26 final dividend
Jun 8, 2026
Cipla has notified exchanges and shareholders about the framework for tax deduction at source on a proposed final dividend of ₹13 per equity share for the financial year ended 31 March 2026, to be considered at its 90th Annual General Meetin...
Cipla Sets Fully Digital 90th AGM with Expanded E-Voting Access
Jun 1, 2026
Cipla Ltd has scheduled its 90th Annual General Meeting for 25 June 2026 at 2:00 p.m. IST, to be conducted via video conferencing, with shareholders able to access the AGM notice and the integrated annual report for FY 2025-26 on the company’...
Cipla Files FY26 Business Responsibility and Sustainability Report
Jun 1, 2026
Cipla Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year to Indian stock exchanges and the Luxembourg Stock Exchange in compliance with SEBI’s disclosure regulations. The report, coveri...
Cipla Sets 90th AGM via Video Conferencing, Confirms Record Date for Final Dividend
May 21, 2026
Cipla has notified stock exchanges that it has published a newspaper advertisement announcing its 90th Annual General Meeting, which will be conducted via video conferencing. The notice also informs shareholders about the record date for determini...
Cipla approves FY26 results and recommends INR 13 final dividend
May 13, 2026
Cipla Ltd, a major Indian pharmaceutical manufacturer of generic and branded medicines, reported its audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026. The results, along with an unmodified aud...
Cipla Clears FY26 Results, Proposes Rs 13 Final Dividend Per Share
May 13, 2026
Cipla Ltd’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, accompanied by an unmodified auditor’s opinion and a confirmation from the Global Chief Financi...
Cipla Board Clears FY26 Results and Recommends Final Dividend
May 13, 2026
Cipla Ltd has announced that its board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, supported by an unmodified opinion from its statutory auditors. The company has also c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.